414 reports of this reaction
3.6% of all LOTEPREDNOL ETABONATE reports
#4 most reported adverse reaction
DRUG INEFFECTIVE is the #4 most commonly reported adverse reaction for LOTEPREDNOL ETABONATE, manufactured by Bausch & Lomb Incorporated. There are 414 FDA adverse event reports linking LOTEPREDNOL ETABONATE to DRUG INEFFECTIVE. This represents approximately 3.6% of all 11,509 adverse event reports for this drug.
Patients taking LOTEPREDNOL ETABONATE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among LOTEPREDNOL ETABONATE users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for LOTEPREDNOL ETABONATE:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 414 FDA reports for LOTEPREDNOL ETABONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 3.6% of all adverse event reports for LOTEPREDNOL ETABONATE, making it a notable side effect.
If you experience drug ineffective while taking LOTEPREDNOL ETABONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.